Per-Patient Costs of Metastatic Prostate Cancer Estimated at $31,427
TUESDAY, Dec. 27, 2022 (HealthDay News) — The estimated annual per-patient costs attributable to metastatic prostate cancer are $31,427, according to a study published in the January issue of Urology Practice.T. Anders Olsen, from the Emory Universit…
Learn MoreOn-Site Genetic Testing for Prostate Cancer Increases Patient Compliance
TUESDAY, Dec. 27, 2022 (HealthDay News) — The implementation of an on-site, guideline-based genetic testing model for prostate cancer patients significantly improves compliance with genetic testing, according to a study published in the January issue…
Learn MoreU.S. Men’s Race, Residence Could Raise Odds for Fatal Prostate Cancer
TUESDAY, Dec. 27, 2022 (HealthDay News) — The color of his skin and where he lives may influence an American man’s odds of dying from prostate cancer, a new study reveals.Black men and men living in the Western United States face the most dire progno…
Learn MoreTrends in Genitourinary Cancers Examined in the United States
WEDNESDAY, Dec. 21, 2022 (HealthDay News) — The highest incidence rates of bladder cancer are seen in the Northeast, while the West has the highest deaths rates for prostate cancer among non-Hispanic White men, according to a study published online D…
Learn MoreMRI-Targeted Biopsy Beneficial for Men With Elevated PSA
THURSDAY, Dec. 8, 2022 (HealthDay News) — For men with elevated prostate-specific antigen (PSA) levels, magnetic resonance imaging (MRI)-directed targeted biopsy seems better for screening and early detection than systematic biopsy, according to a st…
Learn MoreMelanoma Diagnosis Linked to Increased Risk of Prostate Cancer
TUESDAY, Nov. 29, 2022 (HealthDay News) — Melanoma diagnosis is associated with increased risk of subsequent prostate cancer, according to a study published online Nov. 1 in the British Journal of Cancer.Sam Egger, from the University of Sydney, and …
Learn MoreTreatment Without ADT Delays Initiation of Systemic Therapy in Prostate Cancer
MONDAY, Nov. 21, 2022 (HealthDay News) — For prostate cancer patients with a solitary oligometastatic lesion, metastasis-directed therapy without androgen deprivation therapy (ADT) can delay initiation of systemic therapy, according to a study publis…
Learn MoreSequencing of ADT, RT Examined in Localized Prostate Cancer
MONDAY, Oct. 31, 2022 (HealthDay News) — When short-term androgen-deprivation therapy (ADT) is indicated in combination with prostate-only radiotherapy (PORT) for localized prostate cancer, concurrent/adjuvant ADT may result in better outcomes, accor…
Learn MorePatients Favor Single-Port Robotic System for Uro-Oncology Surgery
MONDAY, Oct. 31, 2022 (HealthDay News) — For patients undergoing urologic oncology procedures, use of the da Vinci single-port (SP) robotic system is perceived favorably by patients compared with a multiport platform, according to a study published i…
Learn MoreSiguen bajando las tasas de mortalidad por cáncer en EE. UU.
JUEVES, 27 de octubre de 2022 (HealthDay News) — Las estadísticas más recientes del Instituto Nacional del Cáncer (NCI) de EE. UU. muestran un declive continuo en el número de estadounidenses que mueren de cáncer, aunque ha habido poco cambio en el n…
Learn More